Item 8.01 Other Events.

On January 4, 2023, the EBMT-EHA released an abstract previously submitted by 2seventy bio, Inc. (the "Registrant") [and Bristol Myers Squibb Company] for presentation at the EBMT-EHA 5th European CAR T-cell meeting. The abstract, available on the EBMT-EHA website, includes key data points from the positive results of the Registrant's KarMMa-3 study of ABECMA (idecabtagene vicleucel).

Results from KarMMa-3, a pivotal Phase 3, open-label, global, randomized, controlled study evaluating ABECMA (idecabtagene vicleucel) compared to standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, and were refractory to their last regimen.

Ide-cel significantly improved progression-free survival versus standard regimens (median [95% CI] 13.3 [11.8-16.1] vs 4.4 [3.4-5.9] months; HR 0.49; 95% CI 0.38-0.65; P<0.0001). Overall response rate was significantly improved with ide-cel versus standard regimens (71% vs 42%; P<0.0001), with deeper, more durable responses.

Full results from the KarMMa-3 study will be presented at the EBMT-EHA 5th European CAR T-cell meeting, taking place from February 8-11, 2023, in Rotterdam, Netherlands.

____________

© Edgar Online, source Glimpses